FRCA Notes


Loperamide


  • A surprise entry in the opioid section, loperamide is a synthetic piperidine derivative much like fentanyl
  • This gives it MOP receptor agonist properties
  • It is used to treat diarrhoeal illness, including that associated with inflammatory bowel diseases, short bowel syndrome and chemotherapy-induced diarrhoea
  • Usual dose 2-4mg, up to 16mg/day

  • Loperamide is administered orally, and it exerts its MOP agonist effect in the GI tract
  • Entry from the GI tract into the systemic circulation is limited by the action of P-glycoprotein, and systemic levels are further reduced by hepatic 1st pass metabolism
  • What little systemic loperamide there is also fails to cross the BBB due to the action of P-glycoprotein
  • This generally limits its effects to the peripheral nervous system

  • These intrinsic mechanisms can be overcome by those seeking to use loperamide as a drug of abuse by two mechanisms:
    1. Extremely high doses of loperamide (>70mg), which saturate P-glycoprotein and can lead to CNS effects
    2. Use of P-glycoprotein inhibitors such as quinidine, ketoconazole, ritonavir

  • It is metabolised to an MPTP-like compound which, unlike actual MPTP, is not neurotoxic